Oculogenex is a biopharmaceutical company founded and directed by an ophthalmologist retinal surgeon with patients in mind. It was founded out of passion and frustration shared with patients losing vision due to lack of therapeutic options. We have professional and scientific experience with retinal diseases, genetic variations in retinal and optic nerve diseases. We have built a team of experts in animal models of macular degeneration, antioxidant therapies for macular degeneration, medical and surgical treatments of retinal diseases and drug delivery methods. This specialized team has been built to utilize genetic engineering technology to improve vision for patients with degenerative eye diseases.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 2250 W Whittier Blvd, Suite 300,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.oculogenex.com
- Keywords
- Gene Therapy, Biotechnology, Biopharmaceuticals, Macular Degeneration, Retinal Disease, Ophthalmology, Retina, Drug Delivery.
- HQ
- La Habra, California
Oculogenex Questions
Oculogenex's website is http://www.oculogenex.com
Oculogenex's LinkedIn profile is https://www.linkedin.com/company/oculogenex
Oculogenex has
4 employees.
View email and phone details for 4
employees at Oculogenex.
Oculogenex's industry is
Biotechnology Research
Oculogenex's top competitors are
Nearsight,
Behavioral Pharma,
Aurion Biotech,
Cellviva,
Lumithera, Inc.,
Ocugen,
Cambridge Gene Therapy Limited,
Zymo Research Corp,
Amydis, Inc.,
Eyecelerator.
Oculogenex's categories are Biotechnology Research
Oculogenex's founding year is 2020
